close
close

See high -growing technology stocks in Europe in March 2025

In the middle of a background of global trade policy uncertainty and the mixed economic signals, the European market has shown resilience, with the Germany's Dax index increasing by over 2%, although the concerns are impaired. Since the European Central Bank adapts its monetary policy to cope with inflation and growth problems, investors observe the high-growing tech shares that can benefit from increased infrastructure expenditure and innovation-driven options.

name

Sales growth

Profit growth

Growth assessment

Elicera therapeutics

63.53%

97.24%

★★★★earch

Pharma Mar

24.24%

40.82%

★★★★earch

Bonesupport Holding

30.48%

50.17%

★★★★earch

CD project

27.71%

41.31%

★★★★earch

Yubico

20.88%

26.53%

★★★★earch

Xbrane Biopharma

73.73%

139.21%

★★★★earch

Devyser Diagnostics

26.50%

94.65%

★★★★earch

Elliptical laboratories

49.76%

88.21%

★★★★earch

Ascelia Pharma

46.09%

66.93%

★★★★earch

Scolon

29.71%

91.18%

★★★★earch

Click here to display the full list of 246 shares from our European high -awake technician and AI shares.

Let us get out of the screen in some first -class options.

Simply wall st -growth level: ★★★★ ☆itch

Overview: Zealand Pharma A/S is a biotechnology company that focuses on the discovery, development and marketing of medication on a peptide basis in Denmark and the USA, with a market capitalization of DKK42.53 billion.

Operations: Zealand Pharma mainly achieves revenue from his biotechnology segment, which corresponds to -62.69 million on DKKKK. The company's business activity is about peptide base medication in Denmark and the United States.

Zealand Pharma, which navigates with high operations through the biotech landscape, shows a robust sales growth course of 22.3% per year and significantly exceeds the 8.9% of the Danish market. Despite the current unprofitable and a forecast average decline in profit of 4.7% in the next three years, strategic maneuvers such as recent cooperation with Roche and an aggressive attitude underneath underline their commitment to innovations. The inclusion of the company in the OMX Nordic 40-Index and the ongoing efforts to expand its product pipeline with strict FDA engagements underline both challenges and potential when using the latest biotechnological progress for growth.

CPSE: zeal yields and sales growth as on March 2025

Simply wall st -growth level: ★★★★★ ☆

Overview: Partec AG specializes in the development, production and delivery of supercomputer and quantum computer solutions with a market capitalization of € 280 million.